1
|
Charlès L, Lupon E, Sheth T, Camuzard O, Lellouch AG, Shende C, Farquharson S, Safa K, Cetrulo CL. Immunosuppressant drug monitor: A non-invasive device to measure tacrolimus level in the saliva of transplanted patients. Int J Pharm 2024; 653:123858. [PMID: 38286196 DOI: 10.1016/j.ijpharm.2024.123858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Revised: 01/22/2024] [Accepted: 01/24/2024] [Indexed: 01/31/2024]
Abstract
Solid organ and vascularized composite allograft transplantation are pivotal in enhancing both life expectancy and quality of life. However, the significant risk of donor tissue rejection requires lifelong immunosuppressive therapy. Tacrolimus, a common component of immunosuppressive regimens, offers effectiveness in preventing organ rejection but poses challenges due to its narrow therapeutic window and toxicity, making it essential to carefully monitor its concentration. Tacrolimus trough levels are currently measured in blood, requiring frequent blood draws from patients, and results are available after 3 to 6 h. To address the need for a fast, minimally-invasive, and simple method to monitor tacrolimus concentrations, we have assessed a new device for at-home analysis, the Immunosuppressant Drug Monitor (IDM) that can extract, identify and quantify tacrolimus in saliva within 15 min. We included males and females hospitalized at Massachusetts General Hospital Transplant Unit, between the ages of 21 and 65 years, and treated with Tacrolimus. Informed consent, demographic and treatment data were collected. Each subject was asked to provide a 5 mL saliva sample that was de-identified and processed by the IDM, while a 5 mL blood sample was drawn and supplied to the MGH clinical lab for analysis by the current standard, immunoassays. The predicted tacrolimus concentration found in saliva was compared to the blood trough level results. 62 samples from 31 different patients were obtained. The male to female ratio and ethnicity distribution were well balanced. The majority of patients were within 30 days of initiating tacrolimus treatment. After IDM calibration and exclusion, 21 samples were measured by the IDM. Using an exponential function fit, the IDM showed a correlation of R2 = 0.39 between the saliva Test Line absorption and the measured tacrolimus concentration in blood, with an average absolute error of 1.8 ng/mL. Our results demonstrate a clear correlation between blood and saliva measurements. The IDM provided promising results to monitor immunosuppressant drug concentrations in patients after transplantation. Future larger studies will further develop the correlation, and the IDM's potential impact on patient outcomes.
Collapse
Affiliation(s)
- Laura Charlès
- Vascularized Composite Allotransplantation Laboratory, Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
| | - Elise Lupon
- Vascularized Composite Allotransplantation Laboratory, Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Plastic and Reconstructive Surgery, Institut Universitaire Locomoteur et du Sport, Pasteur 2 Hospital, University Côte d'Azur, Nice, France; Department of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, USA
| | - Tia Sheth
- Vascularized Composite Allotransplantation Laboratory, Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Olivier Camuzard
- Department of Plastic and Reconstructive Surgery, Institut Universitaire Locomoteur et du Sport, Pasteur 2 Hospital, University Côte d'Azur, Nice, France.
| | - Alexandre G Lellouch
- Vascularized Composite Allotransplantation Laboratory, Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, USA; Innovative Therapies in Haemostasis, INSERM UMR-S 1140, University of Paris, Paris F-75006, France.
| | - Chetan Shende
- Real-Time Analyzers Inc., 362 Industrial Park Road, Unit 8, Middletown, CT 06457, USA.
| | - Stuart Farquharson
- Real-Time Analyzers Inc., 362 Industrial Park Road, Unit 8, Middletown, CT 06457, USA.
| | - Kassem Safa
- Division of Nephrology & Transplant Center, Massachusetts General Hospital, Boston, MA, USA.
| | - Curtis L Cetrulo
- Vascularized Composite Allotransplantation Laboratory, Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, USA.
| |
Collapse
|
2
|
Glahn-Martínez B, Jurado-Sánchez B, Benito-Peña E, Escarpa A, Moreno-Bondi MC. Magnetic Janus micromotors for fluorescence biosensing of tacrolimus in oral fluids. Biosens Bioelectron 2024; 244:115796. [PMID: 37922810 DOI: 10.1016/j.bios.2023.115796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Revised: 10/03/2023] [Accepted: 10/26/2023] [Indexed: 11/07/2023]
Abstract
Tacrolimus (FK506) is a macrolide lactone immunosuppressive drug that is commonly used in transplanted patients to avoid organ rejection. FK506 exhibits high inter- and intra-patient pharmacokinetic variability, making monitoring necessary for organ graft survival. This work describes the development of a novel bioassay for monitoring FK506. The bioassay is based on using polycaprolactone-based (PCL) magnetic Janus micromotors and a recombinant chimera receptor that incorporates the immunophilin tacrolimus binding protein 1A (FKBP1A) tagged with Emerald Green Fluorescent Protein (EmGFP). The approach relies on a fluorescence competitive bioassay between the drug and the micromotors decorated with a carboxylated FK506 toward the specific site of the fluorescent immunophilin. The proposed homogeneous assay could be performed in a single step without washing steps to separate the unbound receptor. The proposed approach fits the therapeutic requirements, showing a limit of detection of 0.8 ng/mL and a wide dynamic range of up to 90 ng/mL. Assay selectivity was evaluated by measuring the competitive inhibition curves with other immunosuppressive drugs usually co-administered with FK506. The magnetic propulsion mechanism allows for efficient operation in raw samples without damaging the biological binding receptor (FKBP1A-EmGFP). The enhanced target recognition and micromixing strategies hold considerable potential for FK506 monitoring in practical clinical use.
Collapse
Affiliation(s)
- Bettina Glahn-Martínez
- Department of Analytical Chemistry, Physical Chemistry and Chemical Engineering, University of Alcala, Alcala de Henares, 28805, Madrid, Spain; Department of Analytical Chemistry, Faculty of Chemistry, Universidad Complutense de Madrid, Plaza de las Ciencias, Ciudad Universitaria, 28040, Madrid, Spain
| | - Beatriz Jurado-Sánchez
- Department of Analytical Chemistry, Physical Chemistry and Chemical Engineering, University of Alcala, Alcala de Henares, 28805, Madrid, Spain; Chemical Research Institute "Andres M. del Rio", University of Alcala, Alcala de Henares, Madrid, E28805, Spain.
| | - Elena Benito-Peña
- Department of Analytical Chemistry, Faculty of Chemistry, Universidad Complutense de Madrid, Plaza de las Ciencias, Ciudad Universitaria, 28040, Madrid, Spain.
| | - Alberto Escarpa
- Department of Analytical Chemistry, Physical Chemistry and Chemical Engineering, University of Alcala, Alcala de Henares, 28805, Madrid, Spain; Chemical Research Institute "Andres M. del Rio", University of Alcala, Alcala de Henares, Madrid, E28805, Spain.
| | - María C Moreno-Bondi
- Department of Analytical Chemistry, Faculty of Chemistry, Universidad Complutense de Madrid, Plaza de las Ciencias, Ciudad Universitaria, 28040, Madrid, Spain
| |
Collapse
|
3
|
Chen F, Yang X, Li H, Zeng X, Deng Z, Wang H, Jin Y, Qiu C, Shi Z. Improved LC-MS/MS method for the simultaneous quantification of tacrolimus and cyclosporine A in human blood and application to therapeutic drug monitoring. Biomed Chromatogr 2023; 37:e5751. [PMID: 37772369 DOI: 10.1002/bmc.5751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2023] [Revised: 08/28/2023] [Accepted: 09/07/2023] [Indexed: 09/30/2023]
Abstract
In order to facilitate therapeutic drug monitoring of tacrolimus and cyclosporine A in clinical practice, a simple, rapid, robust, sensitive and specific LC-MS/MS assay was developed and validated for the simultaneous determination of tacrolimus and cyclosporine A in human whole blood. Erythrocytes were destroyed using internal standard solution with 10% (w/v) zinc sulfate in water. The analytes were extracted from 100 μl of whole blood by protein precipitation with acetonitrile. Chromatographic separation was conducted on a Kinetex PFP column (60°C) by a gradient elution with a flow rate of 0.450 ml/min in 2.5 min. Quantitative analysis was performed using electrospray ionization and multiple reaction monitoring in positive ionization mode. The method was fully validated as per current guidelines on bioanalytical methodologies of the US Food and Drug Administration and European Medicines Agency. The method developed was applied successfully in analyzing clinical samples from patients administered tacrolimus or cyclosporine A. The sample treatment procedure was rationalized and improved to fulfill the complete target extraction. The chromatography conditions were optimized to achieve rapid and accurate quantification of both analytes. This method may be beneficial as a constructive input for the therapeutic drug monitoring of tacrolimus and cyclosporine A in obtaining individualized therapy.
Collapse
Affiliation(s)
- Feng Chen
- Department of Clinical Pharmacy, Hunan University of Medicine General Hospital, Huaihua, China
| | - Xiaoxia Yang
- Department of Endocrine Metabolism and Clinical Nutrition, Hunan University of Medicine General Hospital, Huaihua, China
| | - Huanhuan Li
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China
- School of Pharmacy, Queen's University Belfast, Belfast, UK
| | - Xiaodan Zeng
- Department of Clinical Pharmacy, Hunan University of Medicine General Hospital, Huaihua, China
- Department of Evidence-Based Medicine and Clinical Center, Hunan University of Medicine General Hospital, Huaihua, China
| | - Ziwei Deng
- Department of Clinical Pharmacy, Hunan University of Medicine General Hospital, Huaihua, China
- Department of Evidence-Based Medicine and Clinical Center, Hunan University of Medicine General Hospital, Huaihua, China
| | - Hongqiang Wang
- Department of Clinical Pharmacy, Hunan University of Medicine General Hospital, Huaihua, China
- Department of Evidence-Based Medicine and Clinical Center, Hunan University of Medicine General Hospital, Huaihua, China
| | - Yuanxiang Jin
- Department of Clinical Pharmacy, Hunan University of Medicine General Hospital, Huaihua, China
- Department of Evidence-Based Medicine and Clinical Center, Hunan University of Medicine General Hospital, Huaihua, China
| | - Chengfeng Qiu
- Department of Clinical Pharmacy, Hunan University of Medicine General Hospital, Huaihua, China
- Department of Evidence-Based Medicine and Clinical Center, Hunan University of Medicine General Hospital, Huaihua, China
| | - Zhihua Shi
- Department of Clinical Pharmacy, Hunan University of Medicine General Hospital, Huaihua, China
- Department of Evidence-Based Medicine and Clinical Center, Hunan University of Medicine General Hospital, Huaihua, China
| |
Collapse
|
4
|
Development of an agglutination-enhancement immunoturbidimetric tacrolimus assay with improved sensitivity. J Pharm Biomed Anal 2021; 205:114290. [PMID: 34358795 DOI: 10.1016/j.jpba.2021.114290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Revised: 07/24/2021] [Accepted: 07/26/2021] [Indexed: 11/24/2022]
Abstract
Accurate quantification of low level of blood drugs by Latex enhanced immunoturbidimetric assay (LEITA) remains a challenge due to its inherent limited sensitivity. To deal with this problem, we designed a new agglutination-enhancement strategy, and applied it for development of a highly sensitive and accurate tacrolimus LEITA. By this principle, a very small amount of biotin labeled anti-tacrolimus monoclonal antibodies (BLATMA) can arise agglutination strong enough for accurate reading of the increased absorbance since the BLATMA bears multiple biotin molecules, and the agglutination mediated by BLATMA can be inhibited by a similarly small amount of tacrolimus when the drug binds to BLATMA, giving rise to an improved sensitivity. The limit of detection (LOD) and functional sensitivity obtained by the proposed tacrolimus LEITA was 0.22 ng/mL and 0.59 ng/mL, respectively, 8-20 times more sensitive than the conventional drug-latex or antibody-latex based direct inhibition LEITA formats. Good precision was observed in the whole range of clinically significant tacrolimus concentration. The reliability of the tacrolimus LEITA was demonstrated by its strong correlation with both liquid chromatography-tandem mass spectrometry (LC-MS/MS) (R2 = 0.977, slope = 0.998) and the ABBOTT tacrolimus chemiluminescent magnetic immunoassay (CMIA) (R2 = 0.982, slope = 1.01) in the analysis of 119 clinical samples. It's concluded that the agglutination-enhancement strategy can be applied to construct highly sensitive LEITA for accurate tacrolimus analysis; owing to the improved sensitivity, this technique can be expected not only to improve the reliability of LEITA for low-level drug monitoring, but also to broaden the scope of analytes detectable by LEITA.
Collapse
|
5
|
Wu L, Ye Z, Zhang X, Cheng Y, Zheng L, Qiu H, Liu X. Comparison of sample preparation methods, validation of an UPLC-MS/MS procedure for the quantification of cyclosporine A in whole blood sample. J Pharm Biomed Anal 2020; 193:113672. [PMID: 33129116 DOI: 10.1016/j.jpba.2020.113672] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Revised: 10/01/2020] [Accepted: 10/03/2020] [Indexed: 02/07/2023]
Abstract
Current main methods for therapeutic drug monitoring (TDM) of cyclosporine A (CsA) are immunoassays and liquid chromatography tandem mass spectrometry. The sample pretreatment of these methods is mainly based on extraction of drug which is bound to erythrocytes by divalent heavy metal ions (such as zinc and copper). Although these methods are effective for whole blood drug extraction and measurement, the pollution of heavy metals in sample pretreatment process will have potential negative impact on environment and human health. To overcome the pollution problem, in this study we have developed and validated an UPLC-MS/MS method for CsA determination in whole blood samples using physical pretreatment method. According to the characteristics of erythrocytes, a series of physical pretreatment methods, including sonication, freeze-thaw and osmotic burst, have been developed and evaluated. The results showed that the osmotic burst method was an effective way for drug extraction from erythrocytes. The lower limit of quantitation for CsA was 25 ng/mL, the within-run and between-run coefficient of variations were both less than 11.6 %. The agreement of the UPLC-MS/MS methods using these two sample pretreatment was evaluated by Bland-Altman plot and the two-tailed Student's T-test. Comparison studies show that the effect of erythrocyte fragmentation by osmotic burst is similar to that of zinc sulfate method. The CsA measurement of 103 whole blood samples obtained by these two UPLC-MS/MS assays were no significant difference. These results demonstrate that the sample pretreatment by osmotic burst method is an eco-friendly and precise method for detecting the whole blood CsA concentration and therapeutic drug monitoring of CsA.
Collapse
Affiliation(s)
- Lingjie Wu
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, China; Clinical Research Center for Phase I, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, China; The Liver Center of Fujian Province, Fujian Medical University, Fuzhou 350025, China
| | - Zhenjie Ye
- Clinical Research Center for Phase I, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, China
| | - Xiaoying Zhang
- Clinical Research Center for Phase I, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, China
| | - Yu Cheng
- Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou 350001, China
| | - Ling Zheng
- Clinical Research Center for Phase I, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, China.
| | - Hongqiang Qiu
- Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou 350001, China.
| | - Xiaolong Liu
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, China; Clinical Research Center for Phase I, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, China; The Liver Center of Fujian Province, Fujian Medical University, Fuzhou 350025, China.
| |
Collapse
|